Table 1 Patients’ characteristics.
From: The heavy chain of 4F2 antigen promote prostate cancer progression via SKP-2
Clinical factor (n = 82) | Median (range) or n (%) |
|---|---|
Age (y) | 66 (50–75) |
cT stage (n) | |
1 | 54 (69.23%) |
2 | 13 (16.67%) |
3 | 11 (14.10%) |
GS (n) | |
6 | 24 (29.27%) |
7 | 37 (45.12%) |
8 | 12 (14.63%) |
9 | 9 (10.98%) |
TST (ng/dL) | 4.64 (0.42–10.9) |
PSA (ng/mL) | 7.87 (2.45–31.78) |
PSAD | 0.30 (0.06–1.44) |
